These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30578710)

  • 1. Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development.
    van Eerde A; Gottschamel J; Bock R; Hansen KEA; Munang'andu HM; Daniell H; Liu Clarke J
    Plant Biotechnol J; 2019 Jul; 17(7):1408-1417. PubMed ID: 30578710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of dengue virus envelope protein domain III-based antigens in tobacco chloroplasts using inducible and constitutive expression systems.
    Gottschamel J; Lössl A; Ruf S; Wang Y; Skaugen M; Bock R; Clarke JL
    Plant Mol Biol; 2016 Jul; 91(4-5):497-512. PubMed ID: 27116001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
    Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
    Front Immunol; 2019; 10():59. PubMed ID: 30761131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of a novel tetravalent dengue vaccine with a Salmonella Typhimurium bacterial ghost and evaluation of its immunogenicity and protective efficacy using a murine model.
    Kim E; Won G; Lee JH
    Vaccine; 2020 Jan; 38(4):916-924. PubMed ID: 31706812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mice immunized with trimethyl chitosan nanoparticles containing DENV-2 envelope domain III elicit neutralizing antibodies with undetectable antibody-dependent enhancement activity.
    Seesen M; Jearanaiwitayakul T; Limthongkul J; Sunintaboon P; Ubol S
    J Gen Virol; 2022 Jul; 103(7):. PubMed ID: 35833704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.
    McBurney SP; Sunshine JE; Gabriel S; Huynh JP; Sutton WF; Fuller DH; Haigwood NL; Messer WB
    Vaccine; 2016 Jun; 34(30):3500-7. PubMed ID: 27085173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
    Batra G; Raut R; Dahiya S; Kamran N; Swaminathan S; Khanna N
    J Virol Methods; 2010 Jul; 167(1):10-6. PubMed ID: 20211204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes.
    Daniell H; Rai V; Xiao Y
    Plant Biotechnol J; 2019 Jul; 17(7):1357-1368. PubMed ID: 30575284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
    Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
    Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes.
    Lecouturier V; Berry C; Saulnier A; Naville S; Manin C; Girerd-Chambaz Y; Crowe JE; Jackson N; Guy B
    Vaccine; 2019 Jul; 37(32):4601-4609. PubMed ID: 29706291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetravalent formulation of polymeric nanoparticle-based vaccine induces a potent immune response against dengue virus.
    Khan RA; Ahmed F; Afroz S; Khan N
    Biomater Sci; 2022 May; 10(11):2917-2928. PubMed ID: 35470821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-response study in mice of a tetravalent recombinant dengue envelope domain III protein secreted from insect cells.
    Shao L; Pang Z; Bi Y; Li Z; Lin W; Li G; Guo Y; Qi J; Niu G
    Infect Genet Evol; 2020 Nov; 85():104427. PubMed ID: 32565359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    J Nanobiotechnology; 2012 Jul; 10():30. PubMed ID: 22794664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C5a receptor-targeting ligand-mediated delivery of dengue virus antigen to M cells evokes antigen-specific systemic and mucosal immune responses in oral immunization.
    Kim SH; Yang IY; Jang SH; Kim J; Truong TT; Van Pham T; Truong NU; Lee KY; Jang YS
    Microbes Infect; 2013 Nov; 15(13):895-902. PubMed ID: 23892099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.